Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 20/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15094452 | 1.00 | GRM5 (0.73) | GRM5 | |
| SCHEMBL2532609 | 0.84 | GRM5 (1.00) | GRM5 | |
| SCHEMBL2520784 | 0.84 | GRM5 (1.00) | GRM5 | |
| SCHEMBL2520787 | 0.84 | GRM5 (1.00) | GRM5 | |
| SCHEMBL2522028 | 0.84 | GRM5 (1.00) | GRM5 | |
| SCHEMBL2535786 | 0.84 | GRM5 (1.00) | GRM5 | |
| SCHEMBL2522031 | 0.84 | GRM5 (1.00) | GRM5 | |
| SCHEMBL12211863 | 0.84 | GRM5 (1.00) | GRM5 | |
| SCHEMBL2518267 | 0.84 | GRM5 (1.00) | GRM5 | |
| SCHEMBL2518261 | 0.84 | GRM5 (1.00) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10603291-B2 | Compositions and methods for treating metabolic disorders | ANJI PHARMA (US) LLC (US) | 2020-03-31 | — | — | US | disclosed |
| US-20180008561-A1 | Compositions and Methods for Treating Metabolic Disorders | ANJI PHARMACEUTICALS INC. | 2018-01-11 | — | — | US | disclosed |
| US-9211263-B2 | Compositions and methods of treating metabolic disorders | ELCELYX THERAPEUTICS, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-20130177604-A1 | Compositions and Methods of Treating Metabolic Disorders | ELCELYX THERAPEUTICS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178456-A1 | ARYLETHYNYL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178456-A1 | ARYLETHYNYL DERIVATIVES | GRM5, GRM1, GRM3 | GRM5 1/4885 |
| US-20130177604-A1 | Compositions and Methods of Treating Metabolic Disorders | FABP2, GPR119, PNLIP | GRM5 1930/4885 |
| US-10603291-B2 | Compositions and methods for treating metabolic disorders | FABP2, GPR119, SI | GRM5 1880/4885 |
| US-20180008561-A1 | Compositions and Methods for Treating Metabolic Disorders | FABP2, GPR119, SI | GRM5 1880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.